Vol 6, No 2 (2019) > Articles >

Perbandingan Penggunaan Efavirenz dan Nevirapine Terhadap Kolesterol LDL Pasien HIV/AIDS

Yusi Anggriani , Evy Yunihastuti , Yulia Trisna , Ade Rosanti , Reise Manninda , Rifka Annisa

 

Abstract:

Gangguan metabolik lipid merupakan kondisi yang sering ditemukan pada pasien HIV (Human Immunodeficiency Virus)/AIDS (Acquired Immuno Deficiency Syndrome) pada pasien yang menggunakan antiretroviral (ARV) lini pertama seperti efavirenz dan nevirapine. Penelitian ini bertujuan untuk membandingkan kolesterol LDL pasien HIV/AIDS pasien yang menggunakan efavirenz dan nevirapine. Penelitian dilakukan secara prospektif selama 2 bulan. Responden penelitian adalah pasien yang menggunakan ARV lini pertama minimal selama enam bulan, berusia ≥18 tahun, bukan wanita hamil, tidak mengidap infeksi oportunistik mycobacterium ovium complex, dan tidak mengkonsumsi antihiperlipidemia, kortikosteroid, retinoid selama 3 bulan terakhir. Jumlah pasien yang digunakan sebanyak 70 orang dan dibagi menjadi dua kelompok. Analisa ststistik T independent digunakan untuk membandingkan kolesterol LDL antara kelompok efavirenz dan neverapine. Kelompok efavirenz memiliki rata-rata kolesterol LDL sebesar 142,31 mg/dL ±41,461, sedangkan nevirapine 126,83 mg/dL ±40,55. Studi menunjukkan pasien yang menggunakan efavirenz memiliki kolesterol LDL lebih tinggi dibandingkan nevirapin namun tidak bermakna secara statistik.



Lipid metabolism disorder is one of common condition among HIV (Human Immunodeficiency Virus)/AIDS (Acquired Immune Deficiency Syndrome) patients who used first line antiretroviral efavirenz and nevirapine. This study was conducted to compare LDL (Low Density Lipoprotein) cholesterol between two group HIV/AIDS patients with efavirenz and nevirapine. The prospective study was performed in 2 months. HIV/AIDS patients who used first line antiretroviral at least for 6 months, aged ≥18 years old, not pregnant, without Mycobacterium ovium complex opportunistic infection and antihyperlipidemic, corticosteroid, retinoid in last 3 months were included. The 70 patients who enrolled in this study were divided into two groups. The independent T test was carried out to analyze the different of LDL cholesterol between two group. The group of patients using efavirenz showed 142.31 ±41,461 mg/dL and the group of nevirapine 126.83 ±40,55 mg/dL LDL cholesterol. This study showed that patient with efavirenze had higher LDL than nevirapine, but not statistically different.



Keywords: HIV/AIDS; Efavirenz; Nevirapine; LDL Cholesterol

Published at: Vol 6, No 2 (2019) pages: 118-123

DOI: 10.7454/psr.v6i2.4225


Access Counter: 1505 views

Full PDF Download

References:

Aini Hayatul Yulia, R. C. (2014). T-CD4+ and Lipid Profile in HIV. Indonesia Journal of Clinical Pathology and Medical Laboratory, 50-56

Anwar, T. B. (2004). Dislipidemia sebagai faktor resiko penyakit jantung koroner. Jakarta

Barlett, J. G. (2000-2001). Medical management of HIV infection. Baltimore: John Hopkins University.

Botham, K. M. (2012). Harper’s illustrated biochemistry: lipid transport & storage. Amerika Serikat: McGraw Hill.

Departemen Kesehatan Republik Indonesia. (2006). Pedoman pelayanan kefarmasian untuk orang dengan HIV/AIDS (ODHA). Jakarta: Direktorat Bina Farmasi Komunitas dan Klinik Ditjen Bina Kefarmasian dan Alat Kesehatan.

Desai M, Joyce V, Bendavid E, Olshen RA, Hlatky M, Chow A, Holodniy M, Barnett P, Owens DK. (2015). Risk of cardiovascular events associated with current exposure to HIV antiretroviral therapies in a US veteran population. Clin Infect Dis, 61(3) 445-52

Direktorat Jenderal Pencegahan dan Pengendalian Penyakit. (2018). Laporan Perkembangan HIV-AIDS & Infeksi Menular Seksual (IMS) Triwulan IV Tahun 2017. Jakarta: Kementerian Kesehatan Republik Indonesia.

Dominiczak, M.H., Wallace, A.M. (2009). Medical biochemistry: biosynthesis of cholesterol and steroids. Philadelphia: Mosby Elseviers.

Eoin R Feeney.; Mallon, Patrick WG. (2011). HIV and HAART-associated dyslipidemia. The open cardiovascular medicine journal, 49.

Feeney, E. R. (2011). HIV and HAART-associated dyslipidemia. The open Cardiovascular medicine journal, 49.

Frank VL, Prahpan P.(2004). Nevirapine and Efavirenz Elicit Different Changes in Lipid Profiles in Antiretroviral Therapy-Naïve Patients Infected with HIV-1. Plos Medicine, 064-074.

Hammer, S. M. (2008). Antiretroviral treatment of adult HIV infection: 2008 recommendtions of the International AIDS Society-USA panel. Jama, 555-570

Jacques, P.-J., Masari, V., & dkk. (2007). Efavirennz to Nevirapine Switch in HIV-1 Infected Patients With Dylipidemia : a randomized controlled study. Oxford Journal, 263-266

Kementerian Kesehatan RI. (2010). Pelayanan Gizi Bagi ODHA. Jakarta: Direktorat Bina Gizi Masyarakat Ditjen Bina Gizi Masyarakat

Kementerian Kesehatan RI. (2010). Riset Kesehatan Dasar. Jakarta: Badan Penelitian dan Pengembangan Kesehatan

Kementerian Kesehatan Republik Indonesia. (2011). Pedoman Nasional Tatalaksana Klinis Infeksi HIV dan Terapi Antiretroviral. Jakarta: Direktorat Jenderal Pengendalian Penyakit dan Penyehatan Lingkungan

Kementerian Kesehatan RI. (2016). Infodation Pusat Data dan Informasi Kementerian Kesehatan RI. Jakarta: Kementerian Kesehatan RI

Kumar, A. S. (2011). Assesment of lipid profile in patients with human immunodeficiency virus (HIV/AIDS) without antiretroviral therapy. Asian Pasific Journal of Tropical Disease, 24-27

Marcus JL, Neugebauer RS, Leyden wa, Chao CR, Xu L, Quesenberry CP Jr, Klein DB, Towner WJ, Horberg MA, Silverberg MJ. (2016). Use of Abacavir and Risk of Cardiovascular Disease Among HIV Infected Individuals. J Acquir Immune Defic Syndr, 71(4) 413-9

Obrikorang, C. Y. (2011). Serum Lipid Profiing In Highly Active Antiretroviral Therapy in HIV Positive Patients In Ghana

Parienti, J. J. (2007). Efavirenz to Nevirapine Switch in HIV-1 infected Patiens with Dyslipidemia. Clinical infectious diseases, 263-266

Pasupathi P, B. G. (2008). Perubahan nilai CD4, Profil Lipid, dan Enzim Hati Pada Pasien HIV/AIDS. J Appl Biomed, 139-145

Rauch, Andri, et al. (2005). “Chronic hepatitis C in HIV-infected patients: low eligibility and applicability of therapy with pegylated interferon-α plus ribavirin.” JAIDS Journal of Acquired Immune Deficiency Syndromes 38, 238-240

Riddler, S. A. (2008). Class-sparing regimens for initial treatment of HIV-1 infection. . New England Journal of Medicine, 2095-2106.

Yulia, A. H., Coriejati, R., & dkk. (2014). T-CD4+ and Lipid Profile in HIV. Indonesian Journal of Clinical Pathology and Medical Laboratory, 50-56.